


LISTING OF THE CLAIMS:

The current claim set should now replace any claim set of record.

1. **(Currently amended)** A complex comprising a compound of one of formula I - VIII, XII or XIII, in association with an adrenomedullin (AM) peptide, wherein formulas I - VIII, XII and

5 XIII are:



wherein:

K is OR₃₂, SR₃₂, or NR₃₃R₃₄ where R₃₂ is H or lower alkyl, and R₃₃ and R₃₄ are the same or different and each is selected from H and lower alkyl;

Ar is aryl optionally substituted with one or more groups selected


10 from -OH, -NH₂, -SH, halogen and hydrocarbyl;

n is an integer from 1-3; and

R₁, R₂ and R₃ are the same or different and is each selected from H, hydrocarbyl and a heterocyclic ring; or

15 R₁ and R₂ together form a heterocyclic ring including the intervening nitrogen, and R₃ is selected from H, hydrocarbyl and a heterocyclic ring; or


R₁ is selected from H or hydrocarbyl and R₂ and R₃ together form a heterocyclic ring including the intervening nitrogen;



wherein:

20 R₄ and R₅ may be the same or different and each is an aryl group substituted with -C(O)K, and optionally further substituted with one or more groups selected from -OH, -NH₂, -SH, halogen, hydrocarbyl and a heterocyclic ring, where K is as defined above; and

m is an integer from 1-3;




wherein:

K is as defined above;

25 Y is selected from CH₂, O, S and NH; and

R₆ is aryl optionally substituted with one or more groups selected from -OH, -NH₂, -SH, halogen, hydrocarbyl and a heterocyclic ring;




Formula IV

wherein:

5 R₇ is aryl optionally substituted with one or more groups selected from -OH, -NH₂, -SH, halogen, a heterocyclic ring and hydrocarbyl; and

R₈ and R₉ are the same or different and are each hydrocarbyl, optionally substituted with one or more halogens or lower alkyl groups, or

10 R₈ and R₉ together form a heterocyclic ring having five, six or seven atoms, including the intervening nitrogen and optionally containing other heteroatoms, and also optionally substituted with one or more halogens or lower alkyl groups;




Formula V

wherein:

K is as defined above; and

15 R₁₀ and R₁₁ are the same or different and each is an aryl group, optionally substituted with a second aryl group that may be the same or different and the aryl groups may be substituted with one or more groups selected from -OH, -NH₂, -SH, halogen, a heterocyclic ring and hydrocarbyl;



Formula VI

wherein:


p is an integer from 1-3;

M₁, M₂, and M₃ are the same or different and each is S or O;

20 Z is S, [[C]] or P;

R is hydrocarbyl or OR₃₅, where R₃₅ is H or hydrocarbyl; and

R₁₂ and R₁₃ are the same or different and each is hydrocarbyl, a heterocyclic ring or lower alkyl, or R₁₂ and R₁₃ together form a ring;



Formula VII

wherein:


K is as defined above;

r is an integer from 1-3;

R₁₄ and R₁₅ are the same or different and each is aryl optionally substituted with one or more

5 groups selected from -OH, -NH₂, -SH, halogen, a heterocyclic ring and hydrocarbyl; and

R₁₆ and R₁₇ are the same or different and each is hydrocarbyl or a heterocyclic ring;



Formula VIII


wherein:

s is an integer from 1-10;

R₂₀, R₂₁, R₂₂ and R₂₃ are the same or different and each is H, aryl, optionally substituted with

10 one or more halogen or lower alkyl groups, hydrocarbyl and a heterocyclic ring; and

R₁₈, R₁₉ are the same or different and each is aryl optionally substituted with one or more groups selected from -OH, -NH₂, -SH, halogen and lower alkyl;



Formula XII


wherein:

t is an integer from 1-5;

15 u is an integer from 1-2; and

R₂₄ is selected from H, a heterocyclic ring and hydrocarbyl, optionally substituted by halogen;

and



Formula XIII

wherein:


Q is selected from CH₂, NH, S and O; and

Z₁ and Z₃ are the same or different and selected from CH₃, NH₂, OH and SH.
or tautomers thereof,

or a pharmaceutically acceptable salt thereof.

5 2 - 4. (Canceled)

5. (Currently amended) A complex comprising a compound of one of




wherein:

10 v is an integer from 1-3; and


G₁ and G₂ are the same or different and each is selected from CH₂, NH, S and O;

Formula XVI



wherein:

15 R₂₅, R₂₆, R₂₇, and R₂₈ are the same or different and each is selected from halogen and hydrocarbyl, particularly lower alkyl; and



wherein:

K is as defined above, and

R₂₉ and R₃₀ are the same or different and each is aryl optionally substituted with one or more

20 groups selected from -OH, -NH₂, -SH, halogen and hydrocarbyl,

or a pharmaceutically acceptable salt thereof;

in association with a gastric releasing peptide (GRP).


6 - 8. (Canceled)

25


9. **(Currently amended)** A pharmaceutical composition comprising a compound of one of formula I - VIII, XII, or XIII as defined in claim 1, ~~or one of formula XIV, XVI or XVII as defined in claim 5, or a pharmaceutically acceptable salt thereof,~~ and a pharmaceutically acceptable carrier.

5


10. **(Currently amended)** The pharmaceutical composition of claim 9, wherein the compound is of one of formula I' - XIII' as defined in claim 2, ~~or one of formula XIV', XVI', or XVII' as defined in claim 6 or a pharmaceutically acceptable salt thereof,~~ and a pharmaceutically acceptable carrier:




formula I'




formula II'




formula III'




formula IV',




formula V',




formula VI',




formula VII',




formula VIII',




formula IX',




formula X',



formula XI',



formula XII', and



formula XIII'.

11. **(Currently amended)** A method for inhibiting an activity of an AM peptide, comprising contacting the peptide with an effective amount of a pharmaceutical composition comprising the compound of one of formula I - VII as defined in claim [[1]] 9.

12 - 16. **(Canceled)**

17. **(Currently amended)** A method for treating a condition that is mediated by over-expression and/or activity of AM, comprising administering to a patient in need of such treatment an effective amount of a pharmaceutical composition comprising the compound of one of formula I – VII, as defined in claim [[1]] 9.

18 - 19. **(Canceled)**

20. **(Currently amended)** A method for stimulating an activity of an AM peptide, comprising contacting the peptide with an effective amount of a pharmaceutical composition comprising the compound of one of formula VIII, XII or XIII, as defined in claim [[1]] 9.

21 - 25. **(Canceled)**

26. **(Currently amended)** A method for treating a condition that is mediated by under-expression and/or activity of AM, comprising administering to a patient in need of such treatment an effective amount of a pharmaceutical composition comprising the compound of one of formula VIII, XII or XIII, as defined in claim [[1]] 9.

27 - 28. **(Canceled)**

29. **(Currently amended)** A method for inhibiting an activity of a GRP peptide, comprising contacting the peptide with an effective amount of a pharmaceutical composition comprising compound of formula XIV or XVI, as defined in claim 5 76.

30 - 34. **(Canceled)**

35. **(Currently amended)** A method for treating a condition that is mediated by over-expression and/or activity of GRP, comprising administering to a patient in need of such treatment an effective amount of a pharmaceutical composition comprising the compound of formula XIV or XVI, as defined in claim 5 76.

36 - 37. **(Canceled)**

38. (Currently amended) A method for stimulating an activity of a GRP peptide, comprising contacting the peptide with an effective amount of a pharmaceutical composition comprising the compound of formula XVII, as defined in claim 5 76.

39 - 43. (Canceled)


44. (Currently amended) A method for treating a condition that is mediated by under-expression and/or activity of GRP, and/or that would benefit from increased expression of GRP comprising administering to a patient in need of such treatment an effective amount of a pharmaceutical composition comprising the compound of formula XVII, as defined in claim 5 76.

45 - 46. (Canceled)

47. (Currently amended) A method for detecting an AM peptide, comprising
contacting a sample suspected of containing the peptide with a pharmaceutical composition comprising one or more detectably labeled compounds of formula I through VIII, or formula XII through XIII, as defined in claim [[1]] 9, and
detecting labeled compound that is associated with the peptide.

48. (Canceled)

49. (Currently amended) A method for detecting a GRP peptide, comprising
contacting a sample suspected of comprising the peptide with a pharmaceutical composition comprising one or more detectably labeled compounds of formula XIV, XVI or XVII, as defined in claim 5 76 or



Formula XV

wherein

R₁ is: -R₅-(CH₂)_n-CH(R₆)OH, and R₅ is NH, S or O, R₆ is H or CH₃; and n is an integer from 1-4;

R₂ is NH₂, substituted amino or acetamide;

R₃ is H, halogen, CH₃, or CF₃; and

R₄ is H, alkyl, substituted alkyl, alkenyl, alkoxy or halogen; and

detecting labeled compound that is associated with the peptide.

50 - 52. (Canceled)

53. (Currently amended) A kit suitable for treating a subject suffering from a condition mediated by aberrant expression and/or activity of adrenomedullin (AM), comprising a pharmaceutical composition comprising one or more compounds of formula I - VIII, XII or XIII, as defined in claim ~~4~~ 9, ~~or a pharmaceutical composition comprising said compound(s) and a pharmaceutically acceptable carrier~~, and, optionally, a container or packaging material.

54. (Canceled)

55. (Currently amended) A kit suitable for treating a subject suffering from a condition mediated by an aberrant expression and/or activity of gastrin releasing peptide (GRP), comprising a pharmaceutical composition comprising one or more of the compounds of formula XIV, XVI or XVII, as defined in claim ~~5~~ 76, ~~or a pharmaceutical composition comprising said compound(s) and a pharmaceutically acceptable carrier~~, and, optionally, a container or packaging material.

56. (Canceled)

57. (Currently amended) A kit suitable for detecting an AM peptide, comprising
a) a pharmaceutical composition comprising one or more compounds selected from formula I - VIII, XII ~~or~~ and XIII, as defined in claim ~~[[1]]~~ 9, ~~which~~ wherein the compound is detectably labeled, and, optionally,

b) means to detect the labeled compound associated with (bound to) the peptide.

58. (Canceled)

59. (Currently amended) A kit suitable for detecting a GRP peptide, comprising

a) a pharmaceutical composition comprising one or more compounds selected from formula XIV, XVI, XVII, ~~as defined in claim 5~~ and XV, as defined in claim 49, which wherein the compound is detectably labeled, and, optionally,

b) means to detect the labeled compound associated with (bound to) the peptide.

60 - 61. (Canceled)

62. (Previously presented) A method for inhibiting GRP-mediated angiogenesis in a subject in need of such treatment, comprising administering to the subject an effective amount of an agent that inhibits GRP,

provided that the GRP-mediated angiogenesis is not angiogenesis involved in tumor growth or metastasis.

63. (Previously presented) A method for preventing or treating condition mediated by GRP-mediated angiogenesis in a subject in need of such treatment, comprising administering to the subject an effective amount of an agent that inhibits GRP,

provided that the condition is not angiogenesis dependent tumor growth.

64 - 73. (Canceled)


74. (Currently amended) A method for treating low blood pressure or an eating disorder in a subject in need of such treatment, comprising administering to the subject an effective amount of a pharmaceutical composition comprising the compound of formula XV as defined in claim 49.

75. (Canceled)


76. (New) A pharmaceutical composition comprising a compound of one of formula XIV, XVI or XVII as defined in claim 5, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

77. (New) A pharmaceutical composition of claim 76, wherein the compound is one of formula XIV', XVI' or XVII', or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier:


Formula XIV',



Formula XVI',



or the corresponding quinone



or Formula XVII'

